NeuroneticsSTIM
STIM
About: Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Employees: 201
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
51% more capital invested
Capital invested by funds: $8.05M [Q3] → $12.2M (+$4.1M) [Q4]
8% less funds holding
Funds holding: 48 [Q3] → 44 (-4) [Q4]
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
11.49% less ownership
Funds ownership: 34.92% [Q3] → 23.43% (-11.49%) [Q4]
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
Research analyst outlook
We haven’t received any recent analyst ratings for STIM.
Financial journalist opinion
Based on 4 articles about STIM published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 15,750 shares of the Company's common stock (RSUs) to two new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company.
Neutral
GlobeNewsWire
2 weeks ago
Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has priced its previously announced underwritten public offering of its common stock, comprised of 8,000,000 shares of common stock at a public offering price of $2.25 per share, resulting in gross proceeds of approximately $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
Neutral
GlobeNewsWire
2 weeks ago
Neuronetics Announces Launch of Underwritten Public Offering of Common Stock
MALVERN, Pa., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, the Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All shares in the offering are being offered by the Company.
Neutral
GlobeNewsWire
3 weeks ago
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools
Neutral
GlobeNewsWire
2 months ago
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to a new employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by the Compensation Committee of the Company's Board of Directors and were made as material inducements to the recipients' employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan.
Neutral
GlobeNewsWire
2 months ago
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by the Compensation Committee of the Company's Board of Directors and were made as material inducements to the recipients' employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan.
Neutral
GlobeNewsWire
2 months ago
Neuronetics and Greenbrook TMS Announce Closing of Transaction
MALVERN, Pa. and TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”, and together with Neuronetics, the “Combined Company”) today announced that they have successfully completed the previously announced transaction whereby Neuronetics acquired all of the issued and outstanding common shares of Greenbrook (the “Greenbrook Shares”) by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”). Each Greenbrook Share outstanding immediately prior to the effective time of the Arrangement was exchanged for 0.01021 of a share of common stock of Neuronetics (the “Exchange Ratio”) upon closing of the Arrangement.
Neutral
GlobeNewsWire
3 months ago
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. The Company is scheduled to present at 2:30pm Eastern Time the same day via webcast.
Neutral
Seeking Alpha
3 months ago
Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity James Beers - William Blair Danny Stauder - JMP Operator Good day and thank you for standing by. Welcome to the Neuronetics Third Quarter 2024 Financial and Operating Results Conference Call.
Neutral
GlobeNewsWire
3 months ago
CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ: STIM), please note that in the second paragraph of the "Stockholders Approve Acquisition of Greenbrook TMS" section, it should say that the Company expects to achieve cash flow breakeven by the third quarter of 2025, not the second. The corrected release follows:
Charts implemented using Lightweight Charts™